3299 |
Future Perspective on LM Revascularization: From Evidence to Real Practice |
David R. Holmes |
Apr. 25. 17 |
3298 |
Long Term Follow-up(10 Yrs) in Left Main PCI |
Imad Sheiban |
Apr. 25. 17 |
3297 |
Imaging Based Plaque Modification for Left Main PCI |
Andrejs Erglis |
Apr. 25. 17 |
3296 |
[Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is No Longer Surgical Disease. |
Seung-Jung Park |
Apr. 25. 17 |
3295 |
[Debate: Left Main Disease - How to Treat in Contemporary Era?] LM Is Still Surgical Disease. |
David Paul Taggart |
Apr. 25. 17 |
3294 |
A Multicenter Registry Evaluating New Generation Drug-Eluting Stents in Patients with Obstructive Left Main Coronary Artery Disease: DELTA II |
Davide Capodanno |
Apr. 25. 17 |
3293 |
New Meta-Analysis of RCTs in LM Revascularization |
Tullio Palmerini |
Apr. 25. 17 |
3292 |
How Do I Choose Sapien 3, Evolut R or Lotus in My Practice? |
Duk-Woo Park |
Apr. 25. 17 |
3291 |
TAVR for Low Risk and Younger Patients |
Horst Sievert |
Apr. 25. 17 |
3290 |
Bicuspid AS: Future Perspectives of TAVR |
Jung-Min Ahn |
Apr. 25. 17 |